Home > Publications database > Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. > print

001     178678
005     20240229143553.0
024 7 _ |a 10.1158/2159-8290.CD-21-0932
|2 doi
024 7 _ |a pmid:35086922
|2 pmid
024 7 _ |a 2159-8274
|2 ISSN
024 7 _ |a 2159-8290
|2 ISSN
024 7 _ |a altmetric:121639347
|2 altmetric
037 _ _ |a DKFZ-2022-00194
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ruiz-Fernandez de Cordoba, Borja
|0 0000-0002-8638-8012
|b 0
245 _ _ |a Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.
260 _ _ |a Philadelphia, Pa.
|c 2022
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1651577799_6244
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 May 2;12(5):1356-1377
520 _ _ |a Locoregional failure (LRF) in breast cancer patients post-surgery and post-irradiation (IR) is linked to a dismal prognosis. In a refined new model, we identified Enpp1 (Ectonucleotide pyrophosphatase /phosphodiesterase 1/CD203a) to be closely associated with LRF. Enpp1high circulating tumor cells (CTC) contribute to relapse by a self-seeding mechanism. This process requires the infiltration of PMN-MDSC and neutrophil extracellular traps (NET) formation. Genetic and pharmacological Enpp1 inhibition or NET blockade extend relapse-free survival. Furthermore, in combination with fractionated irradiation (FD), Enpp1 abrogation obliterates LRF. Mechanistically, Enpp1-generated adenosinergic metabolites enhance Haptoglobin (Hp) expression. This inflammatory mediator elicits myeloid invasiveness and promotes NET formation. Accordingly, a significant increase in ENPP1 and NET formation is detected in relapsed human breast cancer tumors. Moreover, high ENPP1 or HP levels are associated with poor prognosis. These findings unveil the ENPP1/HP axis as an unanticipated mechanism exploited by tumor cells linking inflammation to immune remodeling favoring local relapse.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Moreno, Haritz
|0 0000-0002-3640-8978
|b 1
700 1 _ |a Valencia, Karmele
|0 0000-0002-2882-7427
|b 2
700 1 _ |a Perurena, Naiara
|0 0000-0003-0874-3389
|b 3
700 1 _ |a Ruedas, Pablo
|b 4
700 1 _ |a Walle, Thomas
|0 P:(DE-He78)51635089578f68fc9efdb61e6a760b64
|b 5
|u dkfz
700 1 _ |a Pezonaga-Torres, Alberto
|b 6
700 1 _ |a Hinojosa, Juan
|0 0000-0003-1868-9910
|b 7
700 1 _ |a Guruceaga, Elisabet
|0 0000-0003-0547-681X
|b 8
700 1 _ |a Pineda-Lucena, Antonio
|0 0000-0002-3532-8781
|b 9
700 1 _ |a Abengozar-Muela, Marta
|b 10
700 1 _ |a Cochonneau, Denis
|b 11
700 1 _ |a Zandueta, Carolina
|b 12
700 1 _ |a Martinez-Canarias, Susana
|b 13
700 1 _ |a Teijeira, Alvaro
|0 0000-0002-7339-4464
|b 14
700 1 _ |a Ajona, Daniel
|b 15
700 1 _ |a Ortiz-Espinosa, Sergio
|0 0000-0001-9192-2956
|b 16
700 1 _ |a Morales, Xabier
|0 0000-0003-0303-9958
|b 17
700 1 _ |a Ortiz de Solorzano, Carlos
|0 0000-0001-8720-0205
|b 18
700 1 _ |a Santisteban, Marta
|0 0000-0003-0625-686X
|b 19
700 1 _ |a Ramos-Garcia, Luis I
|b 20
700 1 _ |a Guembe, Laura
|0 0000-0002-5157-8588
|b 21
700 1 _ |a Strnad, Vratislav
|b 22
700 1 _ |a Heymann, Dominique
|0 0000-0001-7777-0669
|b 23
700 1 _ |a Hervas-Stubbs, Sandra
|0 0000-0003-3391-1516
|b 24
700 1 _ |a Pio, Ruben
|0 0000-0002-6831-6111
|b 25
700 1 _ |a Rodriguez-Ruiz, Maria E
|b 26
700 1 _ |a de Andrea, Carlos E
|b 27
700 1 _ |a Vicent, Silvestre
|0 0000-0002-9457-6881
|b 28
700 1 _ |a Melero, Ignacio
|b 29
700 1 _ |a Lecanda, Fernando
|0 0000-0002-7289-2293
|b 30
700 1 _ |a Martinez-Monge, Rafael
|0 0000-0002-6285-4816
|b 31
773 _ _ |a 10.1158/2159-8290.CD-21-0932
|g p. candisc.0932.2021 -
|0 PERI:(DE-600)2607892-2
|n 5
|p 1356-1377
|t Cancer discovery
|v 12
|y 2022
|x 2159-8274
909 C O |p VDB
|o oai:inrepo02.dkfz.de:178678
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)51635089578f68fc9efdb61e6a760b64
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-15
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER DISCOV : 2021
|d 2022-11-15
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b CANCER DISCOV : 2021
|d 2022-11-15
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Translationale Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21